Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.9% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 0.9% on Wednesday . The company traded as low as $6.39 and last traded at $6.55. Approximately 974,966 shares changed hands during trading, a decline of 83% from the average daily volume of 5,726,458 shares. The stock had previously closed at $6.61.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RXRX. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Needham & Company LLC decreased their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.40.

Recursion Pharmaceuticals Stock Performance

The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -3.94 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The firm’s fifty day moving average is $6.73 and its 200 day moving average is $7.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same period last year, the company posted ($0.38) earnings per share. The company’s revenue was up 30.9% compared to the same quarter last year. On average, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $7.10, for a total value of $213,000.00. Following the completion of the sale, the chief executive officer now directly owns 758,738 shares in the company, valued at approximately $5,387,039.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $6.82, for a total value of $78,068.54. Following the transaction, the director now directly owns 7,144,216 shares in the company, valued at approximately $48,723,553.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Gibson sold 30,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total value of $213,000.00. Following the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at approximately $5,387,039.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 201,682 shares of company stock valued at $1,332,933. Insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Green Alpha Advisors LLC grew its position in Recursion Pharmaceuticals by 2.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after purchasing an additional 1,800 shares during the last quarter. Interchange Capital Partners LLC grew its position in Recursion Pharmaceuticals by 7.3% during the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after buying an additional 2,349 shares in the last quarter. Amalgamated Bank increased its stake in Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the period. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $26,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after purchasing an additional 2,598 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.